| Identification | Back Directory | [Name]
E-7820 | [CAS]
289483-69-8 | [Synonyms]
E-7820
CS-2701
ER 68203-00
E 7820; E-7820
ER68203-00;E7820;E-7820;E 7820;289483-69-8
3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide
N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzene-sulfonamide
Benzenesulfonamide, 3-cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)- | [Molecular Formula]
C17H12N4O2S | [MDL Number]
MFCD09833234 | [MOL File]
289483-69-8.mol | [Molecular Weight]
336.37 |
| Chemical Properties | Back Directory | [Boiling point ]
626.2±65.0 °C(Predicted) | [density ]
1.48±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:67.0(Max Conc. mg/mL);199.19(Max Conc. mM) | [form ]
A crystalline solid | [pka]
8.17±0.30(Predicted) | [color ]
Light yellow to light brown |
| Hazard Information | Back Directory | [Description]
E7820 is a sulfonamide derivative and an angiogenesis inhibitor that inhibits bFGF- and VEGF-stimulated human umbilical vein endothelial cell (HUVEC) proliferation (IC50s = 0.1 and 0.081 μg/ml, respectively).1 It inhibits bFGF- and VEGF-stimulated tube formation of HUVECs in a concentration-dependent manner (IC50s = 0.2 and 0.24 μg/ml, respectively). E7820 selectively decreases the surface expression and mRNA levels of integrin α2 over CD31 and VE-cadherin in HUVECs. In vivo, E7820 (200 and 400 mg/kg) reduces tumor growth and inhibits angiogenesis in a WiDr colorectal cancer mouse xenograft model. It also reduces tumor weight in a panel of seven human colon, breast, pancreas, and kidney cancer mouse xenograft models, completely inhibits tumor growth in KP-1 pancreatic and LoVo colon cancer mouse xenograft models, and inhibits tumor growth in KP-1 and COLO 320DM mouse orthotopic transplantation models.2 | [storage]
Store at -20°C |
|
|